Biotest has been growing earnings at an average annual rate of 47.4%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 10.6% per year.
Key information
47.40%
Earnings growth rate
48.62%
EPS growth rate
Biotechs Industry Growth
17.04%
Revenue growth rate
10.55%
Return on equity
-4.81%
Net Margin
-3.86%
Next Earnings Update
04 Aug 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biotest makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:BIES.F Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 25
635
-24
81
57
31 Dec 24
726
26
83
57
30 Sep 24
707
69
85
68
30 Jun 24
781
164
87
65
31 Mar 24
783
177
86
71
31 Dec 23
685
127
84
67
30 Sep 23
656
91
84
56
30 Jun 23
538
-10
85
57
31 Mar 23
517
-47
84
50
31 Dec 22
516
-32
82
51
30 Sep 22
505
-69
84
51
30 Jun 22
511
-65
83
50
31 Mar 22
512
-54
82
51
31 Dec 21
516
-63
82
52
30 Sep 21
514
-28
77
55
30 Jun 21
507
-33
78
55
31 Mar 21
507
-35
80
56
31 Dec 20
484
-31
80
56
30 Sep 20
466
-34
82
56
30 Jun 20
459
-24
84
54
31 Mar 20
439
-15
83
52
31 Dec 19
419
-5
83
53
30 Sep 19
406
-9
82
52
30 Jun 19
395
-3
82
53
31 Mar 19
390
-6
82
51
31 Dec 18
400
-13
85
49
30 Sep 18
405
18
91
50
30 Jun 18
409
6
91
52
31 Mar 18
400
1
99
54
31 Dec 17
378
-16
100
55
30 Sep 17
257
-48
95
56
30 Jun 17
301
-47
93
52
31 Mar 17
340
-29
89
49
31 Dec 16
408
6
88
48
30 Sep 16
531
128
78
36
30 Jun 16
525
52
88
62
31 Mar 16
526
36
88
72
31 Dec 15
535
27
93
79
30 Sep 15
590
-88
107
93
30 Jun 15
606
3
109
73
31 Mar 15
602
16
110
69
31 Dec 14
582
19
108
67
30 Sep 14
543
27
105
72
30 Jun 14
522
31
98
69
Quality Earnings: BIES.F is currently unprofitable.
Growing Profit Margin: BIES.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIES.F is unprofitable, but has reduced losses over the past 5 years at a rate of 47.4% per year.
Accelerating Growth: Unable to compare BIES.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIES.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: BIES.F has a negative Return on Equity (-4.81%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2025/06/07 04:27
End of Day Share Price
2025/03/10 00:00
Earnings
2025/03/31
Annual Earnings
2024/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotest Aktiengesellschaft is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.